RMS

Basel, Switzerland, September 1, 2026 Novartis has announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials,...

NESS ZIONA, Israel, April 16, 2026 Mapi Pharma Ltd. has announced new clinical findings demonstrating that its Glatiramer Acetate...